Simvastatin 40 mg tablets recalled for manufacturing practice deviations
Accord Healthcare is recalling 1,190,484 bottles of Simvastatin 40 mg tablets distributed in the United States, Puerto Rico, and Canada due to Current Good Manufacturing Practice deviations identified during an FDA inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification indicates potential for adverse health consequences. This recall represents a risk-of-harm product where manufacturing control deviations have been identified but no illnesses or injuries have been reported, placing it at the High severity level per the rubric.
Plain-English summary
Accord Healthcare, Inc. is recalling 1,190,484 bottles of Simvastatin Tablets USP 40 mg across multiple batches. The recall follows an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility. These deviations relate to manufacturing and quality control procedures.
The affected product was distributed throughout the United States, including Puerto Rico, and Canada. The recall affects multiple batches with expiration dates ranging from February 2023 through May 2025. Affected batches are identified by specific lot numbers listed in the recall notice.
Consumers who have this medication should consult their healthcare provider about whether they should continue taking the product or switch to an alternative. Patients should not stop taking their medication without medical guidance. Those with questions about whether their medication is affected should check the lot number on their prescription bottle against the recall information.
The recalled product
- Product
- SIMVASTATIN (SIMVASTATIN)
- Brand
- SIMVASTATIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- Affected units
- 1,190,484
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2103713
- P2103692
- Exp. Date 5/31/2023
- P2104950
- P2104984
- P2104969
- P2104996
- P2105274
- P2105314
- P2105316
- Exp. Date 7/31/2023
- R2101074
- R2101077
- R2101078
- R2101079
- R2101083
- R2101084
- R2101117
- Exp. Date 8/31/2023
- R2101330
UPCs (2)
- 316729006156
- 316729006170
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · SIMVASTATIN
- HighAccord Healthcare Simvastatin 80 mg Tablets Recalled for Manufacturing Practice Violations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
- HighPrescription Drug Simvastatin Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- ModerateAurobindo Recalls Simvastatin Tablets Due to Manufacturing Water Leakage
FDA (Drugs) · 2020-04-22
Same manufacturer · Accord Healthcare, Inc.
See all →- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19